webinar register page

Webinar banner
Digital Health Solution - Disease Management
In what ways can these new technologies contribute to the realization of better outcomes for patients at less cost to overburdened health systems?

Oct 24, 2022 02:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information


Sathya Elumalai,
President & CEO @Aidar Health Inc.
Sathya Elumalai is a healthcare executive with over 15 years of experience working with payers, providers, pharmaceuticals, and patients. At Aidar Health, Inc., Mr. Elumalai has developed a revolutionary tricorder-style health assessment device, MouthLab, which measures 10+ health parameters in 60 seconds, and an AI-enabled enterprise platform, which leverages data science and AI technology, to create a new kind of personalized experience for people suffering with chronic conditions. In addition to his efforts at Aidar Health, Mr. Elumalai also serves as a Dean’s Alumni Advisory Board Member at the Johns Hopkins Carey Business School, Advisory Board Member at George Washington University, Scientific Merit Reviewer at the National Science Foundation, Executive Member of Forbes Business Council, and an Ambassador & Merit Reviewer at the Patient-Centered Outcome Research Institute.
Behold.ai Inc.
Dr. Ashkan Vaziri
PhD, Founder and CEO @BioSensics
Dr. Vaziri is a Founder and CEO of BioSensics, a biomedical firm focused on the development of wearable sensors and digital health platforms for clinical trials and research. Dr. Vaziri work presents a unique combination of academic research, product development, and small business experience. He co-founded BioSensics in 2007, when he was a Research Associate at the Harvard School of Engineering. Since its establishment, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by developing technologies that are now being used by thousands of older adults. BioSensics solutions are now empowering novel healthcare initiatives and important clinical trials in a variety of therapeutic areas. Dr. Vaziri has authored 150+ journal papers and over 250+ conference proceedings with 9,500+ citations, 6 issued/pending patents, and served as Principal Investigator on 20+ NIH/NSF-funded projects.
Butterfly Network Inc.
John Martin, MD @Chief Medical Officer, Butterfly Network, Inc.
Dr. John Martin is the Chief Medical Officer of Butterfly Network, a transformational digital health company that is democratizing medical imaging across the globe. Dr. Martin completed a residency in general surgery and vascular surgery at Parkland Memorial Hospital in Dallas, Texas. He is board certified in vascular surgery and a Fellow of the American College of Surgeons. He served in the United States Air Force for 7 years first as a corpsman and then after completing medical school and training he returned as a Surgeon. He has held multiple positions throughout his career including Chief of Vascular Surgery and Director of Heart and Vascular Services at Anne Arundel Medical Center, President of Cardiology Associates, and Vice President of Physician Operations for MedStar Medical Group. He is the founder and President of the Heart Health Foundation and the award-winning Dare to CARE Program.
Matthieu Leclerc-Chalvet
CEO @Therapixel
Matthieu is the CEO of Therapixel. He has over 30 years’ experience, mostly internationally, in developing and commercializing innovation-based medical devices, across a dozen of medical specialties. His passion is for bringing innovative products to markets and leading multi-national teams. He has worked for large Anglo-Saxon companies such as Medtronic, Smiths Medical and General Electric, but also for startups in biotech, medical imaging, and AI. He lived abroad for 20 years before his return to France for Therapixel. He holds an MSc in Biomedical Engineering from the University of Lyon, France and is an alumnus from INSEAD business school. He is currently completing a PhD on adoption of innovative medical technology.
John Bertrand
CEO and Co-Founder @Digital Diagnostics, Inc.
John Bertrand brings nearly 2 decades of healthcare technology experience to Digital Diagnostics. During his 12-year career with Epic, Bertrand led cross-functional teams in a variety of product, customer success, and business development roles with a focus on commercial growth and expansion. Most recently Bertrand served as Executive in Residence at 8VC, a leading Silicon Valley venture capital firm focused on healthcare technology. His time in this space focused on the application of artificial intelligence and computer vision in healthcare. Through his 15+ years in the healthcare technology industry, he has developed expertise in identifying market opportunities, creating new products, pivoting existing businesses, and building strong teams. During his time at Digital Diagnostics, he strives to benefit patients by transforming the accessibility, affordability, equity, & quality of global healthcare through the application of technology in the medical diagnosis and treatment process.
Jayme Strauss, RN, MSN, MBA, SCRN
Chief Clinical Officer @Viz.ai, Inc.
Jayme Strauss is the Chief Clinical Officer of Viz.ai. Jayme has over 10 years experience as an executive building clinical service lines in the areas of Neuroscience and Oncology. Jayme previously was the Executive Director of Neuroscience at Piedmont Healthcare in Georgia, and Assistant Vice President of Neuroscience and Oncology at Baptist Health South Florida. Jayme is passionate about evolving the way that healthcare is delivered globally, ensuring patients have access to life saving therapies, and moving science forward through research.
Alexandra Moens (Moderator)
Director, Product Marketing @H1
Alexandra Moens is a PharmD who has been part of the clinical industry for over 6 years. Her aim is to make a positive impact on patient lives by working with innovative solutions, implementing enhanced clinical strategies and increasing diversity and equity in the drug development lifecycle. Her scientific background and experience working with pharmaceutical partners hand-in-hand have positively impacted clinical teams to get new insights to successfully manage their portfolio strategy in the fast evolving clinical industry.
Nikolaus Krall
VP, Precision Medicine @Exscientia
Prior to its acquisition by Exscientia, Nikolaus served as the Managing Director of Allcyte, which he had co-founded as a pioneer in AI driven cancer precision medicine in 2017. Originally trained as an organic chemist at the University of Cambridge, he concluded his doctoral studies at ETH Zurich focusing on the engineering of targeted agents for the treatment of kidney cancer and did a postdoc working on the analysis of drug action in primary human tissues at the CeMM Research Centre for Molecular Medicine of the Austrian Academy of Sciences in Vienna.